Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 23:13:854730.
doi: 10.3389/fimmu.2022.854730. eCollection 2022.

Advances of DNA Damage Repair-Related Drugs and Combination With Immunotherapy in Tumor Treatment

Yumin Wang  1   2 , Meihan Duan  3 , Zhouying Peng  1   2 , Ruohao Fan  1 , Yuxiang He  2   4 , Hua Zhang  1 , Wei Xiong  5 , Weihong Jiang  1   2
Affiliations
Review

Advances of DNA Damage Repair-Related Drugs and Combination With Immunotherapy in Tumor Treatment

Yumin Wang et al. Front Immunol. .

Abstract

Cancer therapy has been an important and popular area in cancer research. With medical technology developing, the appearance of various targeted drugs and immunotherapy offer more choices to cancer treatment. With the increase in drug use, people have found more and more cases in which tumors are resistant to DNA damage repair (DDR)-based drugs. Recently, the concept of combination therapy has been brought up in cancer research. It takes advantages of combining two or more therapies with different mechanisms, aiming to benefit from the synergistic effects and finally rescue patients irresponsive to single therapies. Combination therapy has the potential to improve current treatment of refractory and drug-resistant tumors. Among the methods used in combination therapy, DDR is one of the most popular methods. Recent studies have shown that combined application of DDR-related drugs and immunotherapies significantly improve the therapeutic outcomes of malignant tumors, especially solid tumors.

Keywords: DNA damage; DNA repair; combination; immunotherapy; tumor treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
DDR drugs and mechanism of DDR drug in cancer treatment. Left: Represent FDA-approved DNA damage-related drugs. Right: Mechanism of DDR drugs in DNA repair progress.
Figure 2
Figure 2
Combination of DDR drug and immunotherapy in human cancer.
See this image and copyright information in PMC

References

    1. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell (2011) 144(5):646–74. doi: 10.1016/j.cell.2011.02.013 - DOI - PubMed
    1. Aparicio T, Baer R, Gautier J. DNA Double-Strand Break Repair Pathway Choice and Cancer. DNA Repair (Amst) (2014) 19:169–75. doi: 10.1016/j.dnarep.2014.03.014 - DOI - PMC - PubMed
    1. Lord CJ, Ashworth A. BRCAness Revisited. Nat Rev Cancer (2016) 16(2):110–20. doi: 10.1038/nrc.2015.21 - DOI - PubMed
    1. Yang Y. Cancer Immunotherapy: Harnessing the Immune System to Battle Cancer. J Clin Invest (2015) 125(9):3335–7. doi: 10.1172/JCI83871 - DOI - PMC - PubMed
    1. Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH, Jr. A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future. Curr Oncol (2020) 27(Suppl 2):S87–97. doi: 10.3747/co.27.5223 - DOI - PMC - PubMed

Publication types

Substances